Serum Vascular Endothelial Growth Factor-D Levels in Patients With Lymphangioleiomyomatosis Reflect Lymphatic Involvement

被引:99
|
作者
Glasgow, Connie G.
Avila, Nilo A. [3 ]
Lin, Jing-Ping [2 ]
Stylianou, Mario P. [2 ]
Moss, Joel [1 ]
机构
[1] NHLBI, Translat Med Branch, NIH, Div Prevent & Populat Sci, Bethesda, MD 20892 USA
[2] NHLBI, Off Biostat Res, Div Prevent & Populat Sci, Bethesda, MD 20892 USA
[3] NIH, Warren G Magnuson Clin Ctr, Dept Diagnost Radiol, Bethesda, MD 20892 USA
关键词
adenopathy; angiomyolipoma; cystic lung disease; lymphangioleiomyoma; lymphatics; tuberous sclerosis complex; vascular endothelial growth factor-D; TUBEROUS SCLEROSIS COMPLEX; PULMONARY LYMPHANGIOLEIOMYOMATOSIS; TSC2; WOMEN; LAM; LYMPHANGIOMYOMATOSIS; LYMPHANGIOGENESIS; TRANSPLANTATION; MUTATIONS; MECHANISM;
D O I
10.1378/chest.08-1160
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: Lymphangioleiomyomatosis (LAM) is a rare multisystem disorder affecting primarily women of child-bearing age, and characterized by cystic lung destruction, tumors of the kidney (angiomyolipomas [AMLs% and involvement of the axial lymphatics (lymphangioleiomyomas). Patients with LAM experience loss of pulmonary function attributed to the proliferation of abnormal-appearing smooth muscle-like cells (LAM cells). it is possible to group the LAM population by the presence or absence of extrapulmonary involvement (eg, AMLs, lymphangioleiomyomas, chylous effusions). Serum vascular endothelial growth factor (VEGF)-D, a lymphangiogenic factor, is higher in LAM patients than in healthy volunteers and has been proposed as a tool in the differential diagnosis of cystic lung disease. We assessed serum VEGF-D concentrations in relationship to clinical phenotype in LAM patients. Methods: Serum VEGF-D levels were quantified by enzyme immunosorbent assay for 111 patients with LAM and 40 healthy volunteers. VEGF-D levels in patients with pulmonary LAM, with or without extrapulmonary manifestations, were compared to those of healthy volunteers. Results: Serum VEGF-D levels were greater in patients with LAM compared to those of healthy volunteers (p < 0.001). However, when patient samples were grouped based on the extent of lymphatic extrapulmonary involvement (eg, lytnpbaingioleiomyomas and adenopathy), the statistical difference was maintained only for patients with LAM with lymphatic involvement (p < 0.001), not for those patients whose disease was restricted to the lung. Serum VEGF-D levels are a good biomarker for lymphatic involvement (area under the curve [AUC], 0.845; p < 0.0001), and a fair predictor for LAM disease (AUC, 0.7.51; p < 0.0001). Serum levels correlated to CT scan grade (p = 0.033). Conclusions: Serum VEGF-D concentration is a measure of lymphatic involvement in patients with LAM. (CHEST 2009; 135.1293-1300)
引用
收藏
页码:1293 / 1300
页数:8
相关论文
共 50 条
  • [41] Structural determinants of vascular endothelial growth factor-D receptor binding and specificity
    Leppanen, Veli-Matti
    Jeltsch, Michael
    Anisimov, Andrey
    Tvorogov, Denis
    Aho, Kukka
    Kalkkinen, Nisse
    Toivanen, Pyry
    Yla-Herttuala, Seppo
    Ballmer-Hofer, Kurt
    Alitalo, Kari
    BLOOD, 2011, 117 (05) : 1507 - 1515
  • [42] β-catenin inversely regulates vascular endothelial growth factor-D mRNA stability
    Orlandini, M
    Semboloni, S
    Oliviero, S
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (45) : 44650 - 44656
  • [43] Supplementation with α-Tocopherol or β-Carotene Reduces Serum Concentrations of Vascular Endothelial Growth Factor-D, but Not -A or -C, in Male Smokers
    Mondu, Alison M.
    Rager, Helen C.
    Kopp, William
    Virtamo, Jarmo
    Albanes, Demetrius
    JOURNAL OF NUTRITION, 2011, 141 (11): : 2030 - 2034
  • [44] Vascular endothelial growth factor-D modulates oxidant-antioxidant balance of human vascular endothelial cells
    Papiewska-Pajak, Izabela
    Balcerczyk, Aneta
    Stec-Martyna, Emilia
    Koziolkiewicz, Wiktor
    Boncela, Joanna
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2017, 21 (06) : 1139 - 1149
  • [45] Serum Vascular Endothelial Growth Factor C as a Marker of Therapeutic Response to Sirolimus in Lymphangioleiomyomatosis
    Gupta, Nishant
    Hagner, Miles
    Wu, Huixing
    Young, Lisa R.
    Palipana, Anushka
    Szczesniak, Rhonda D.
    McCormack, Francis X.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2021, 18 (01) : 174 - 177
  • [46] Serum vascular endothelial growth factor levels in patients with medullary thyroid carcinoma
    Bugalho, Maria Joao
    Madureira, Deolinda
    Espandinha, Carla
    Font, Ana Paula
    Sobrinho, Luis G.
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2008, 159 (02) : 167 - 169
  • [47] Elevated levels of serum vascular endothelial growth factor in patients with rheumatoid arthritis
    Bilgi, Pinar Tonbaklar
    Cetin, Esra
    Ozgonenel, Levent
    Aslan, Aram
    Aral, Hale
    Inal, Berrin Bercik
    Guvenen, Guvenc
    CLINICAL BIOCHEMISTRY, 2009, 42 (4-5) : 343 - 343
  • [48] Serum and plasma vascular endothelial growth factor levels in testicular cancer patients
    Ferrero, S
    ANNALS OF ONCOLOGY, 2004, 15 (06) : 989 - 990
  • [49] Serum levels of vascular endothelial growth factor elevated in patients with muscular dystrophy
    Saito, Toshio
    Yamamoto, Yuko
    Matsumura, Tsuyoshi
    Fujimura, Harutoshi
    Shinno, Susumu
    BRAIN & DEVELOPMENT, 2009, 31 (08): : 612 - 617
  • [50] ELEVATED SERUM LEVELS OF VASCULAR ENDOTHELIAL GROWTH-FACTOR IN PATIENTS WITH PREECLAMPSIA
    BAKER, PN
    KRASNOW, J
    ROBERTS, JM
    YEO, KT
    OBSTETRICS AND GYNECOLOGY, 1995, 86 (05): : 815 - 821